{"denoms":[{"counts":[{"groupId":"BG000","value":"106"}],"units":"Participants"}],"groups":[{"description":"LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.","id":"BG000","title":"Ribociclib 600 mg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.52","value":"60.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"50"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"90"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Adrenals"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Bladder"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Breast-triple negative"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Cervix"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Cholangio"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Chordoma"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Colorectal"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Esophagus"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Gall bladder ducts"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Gastroesophageal junction"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Gastrointestinal stromal tumor"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Head and neck non-squamous cell carcinoma"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Head and neck squamous cell carcinoma"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Kidneys"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Liver"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Lung non-small cell adenocarcinoma"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Lung non-small cell non-adenocarcinoma"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Lung non-small cell squamous"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Lymphoma"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Mesothelioma"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Neuroendocrine"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Ovarian"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Pancreas"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Penile"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Prostate"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Salivary gland"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Sarcoma"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Skin non-melanoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Thyroid"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Unknown primary"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Uterus"}]}],"description":"Primary tumor type was sponsor adjudicated.","paramType":"COUNT_OF_PARTICIPANTS","title":"Primary tumor type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61"}]}],"title":"Prior antineoplastic radiotherapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"92"}]}],"title":"Prior antineoplastic surgery"},{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}],"title":"Liver metastasis"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of participants who had radiotherapy, surgery and liver metastasis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}]}],"title":"Performance status = 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"70"}]}],"title":"Performance status = 1"}],"description":"ECOG: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light housework, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5 = Dead.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status for participants","unitOfMeasure":"participants"}]}